By Mill Chart
Last update: Jun 27, 2024
Our stock screener has spotted EXELIXIS INC (NASDAQ:EXEL) as an undervalued stock with solid fundamentals. NASDAQ:EXEL shows decent health and profitability. At the same time it remains remains attractively priced. We'll dive into each aspect below.
To assess a stock's valuation, ChartMill utilizes a Valuation Rating on a scale of 0 to 10. This comprehensive assessment considers various valuation aspects, comparing price to earnings and cash flows, while factoring in profitability and growth. NASDAQ:EXEL has achieved a 8 out of 10:
Discover ChartMill's exclusive Profitability Rating, a proprietary metric that assesses stocks on a scale of 0 to 10. It takes into consideration various profitability ratios and margins, both in absolute terms and relative to industry peers. Notably, NASDAQ:EXEL has achieved a 7:
A critical element of ChartMill's stock evaluation is the Health Rating, which spans from 0 to 10. This rating considers multiple health factors, including liquidity and solvency, both in absolute terms and relative to industry peers. NASDAQ:EXEL has received a 7 out of 10:
ChartMill employs its own Growth Rating system for all stocks. This score, ranging from 0 to 10, is derived by evaluating different growth factors, such as EPS and revenue growth, taking into account both past performance and future projections. NASDAQ:EXEL has earned a 6 for growth:
More Decent Value stocks can be found in our Decent Value screener.
Check the latest full fundamental report of EXEL for a complete fundamental analysis.
This is not investing advice! The article highlights some of the observations at the time of writing, but you should always make your own analysis and invest based on your own insights.
42.37
+0.15 (+0.36%)
Find more stocks in the Stock Screener
EXELIXIS INC (NASDAQ:EXEL) shows strong growth fundamentals and a bullish technical setup, making it a stock worth watching for investors seeking growth opportunities.
EXELIXIS INC (NASDAQ:EXEL) shows strong earnings growth, expanding margins, and solid cash flow, making it a standout for growth investors following Louis Navellier’s strategy.
EXELIXIS INC (NASDAQ:EXEL) offers strong growth, solid profitability, and an attractive valuation, making it a compelling choice for investors seeking affordable growth stocks in the biotech sector.
EXELIXIS INC (NASDAQ:EXEL) is an undervalued biotech stock with strong profitability, financial health, and growth potential, making it a candidate for value investors.
EXELIXIS INC (NASDAQ:EXEL) meets Minervini’s Trend Template with strong technicals and high growth momentum, making it a standout in biotech. Review its full technical and fundamental strengths before considering an investment.